The Clinical Trial of Pandemic Influenza Vaccine (Whole-Virion Inactivated, Adjuvanted) on Healthy Adults by Randomized and Double-Blind Design: a Phase II Study

Trial Profile

The Clinical Trial of Pandemic Influenza Vaccine (Whole-Virion Inactivated, Adjuvanted) on Healthy Adults by Randomized and Double-Blind Design: a Phase II Study

Completed
Phase of Trial: Phase II

Latest Information Update: 23 Apr 2013

At a glance

  • Drugs Influenza A virus vaccine-H5N1 (Primary)
  • Indications Influenza A virus H5N1 subtype; Influenza A virus infections
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Sinovac Biotech
  • Most Recent Events

    • 15 Apr 2009 Results published in Clinical Infectious Diseases.
    • 16 May 2008 Production license from the China State Food and Drug Administration (SFDA) for exclusive supply of Panflu to the national stockpiling program.
    • 24 Dec 2007 Status changed from recruiting to completed; this trial has been reported as completed in a Sinovac media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top